important and often defining component of the clinical syndromes of Lewy body disorders: Parkinson's disease and dementia with Lewy bodies. The spectrum of cognitive deficits in these Lewy body diseases encompasses a broad range of clinical features, severity of impairment, and timing of presentation. It is now recognized that cognitive dysfunction occurs not only in more advanced Parkinson's disease but also in early, untreated patients and even in those patients with pre-motor syndromes, such as rapid eye movement behavior disorder and hyposmia. In recent years, the concept of mild cognitive impairment as a transitional or pre-dementia state in Parkinson's disease has emerged. This has led to much research regarding the diagnosis, prognosis, and underlying neurobiology of mild cognitive impairment in Parkinson's disease, but has also raised questions regarding the usefulness of this concept and its application in clinical and research settings. In addition, the conundrum of whether Parkinson's disease dementia and dementia with Lewy bodies represent the same or different entities remains unresolved. Although these disorders overlap in many aspects of their presentations and pathophysiology, they differ in other elements, such as timing of cognitive, behavioral, and motor symptoms; medication responses; and neuropathological contributions. This article examines the spectrum and evolution of cognitive impairment in Lewy body disorders and debates these controversial issues in the field using pointcounterpoint approaches. Cognitive impairment represents an important component of the clinical syndromes of Lewy body disorders: Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The spectrum of impairment ranges broadly in phenotype as well as timing in the disease course. Cognitive deficits can occur in one or more domains, vary in severity, and present differently at various stages of the disease. Studies of incident PD cohorts indicate that cognitive impairment is no longer just a late-stage problem. [1] [2] [3] Dementia, however, remains a troubling complication for a majority of patients with advanced PD 4, 5 and affects quality of life, 6 caregiving, 7 and socioeconomics. 8 Longitudinal studies reveal patient differences in the progression of cognitive deficits and in risk factors for developing PD dementia (PDD). [9] [10] [11] As treatments to prevent dementia or arrest cognitive decline represent critical unmet needs in PD, recent research has focused on the state of mild cognitive impairment (MCI), which has been considered a transitional stage between normal cognition and dementia and one in which cognitive deficits have little to no impact on functional abilities. Although much preceding work has focused on MCI as related to Alzheimer's disease (AD), 12, 13 the MCI construct as specifically designated in PD has only recently emerged, with diagnostic criteria recently proposed.
14 At present, there are many unanswered questions regarding PD-MCI, what PD-MCI represents and whether it is a useful construct for the field. These issues are debated in this article. In addition, this article examines the PDD and DLB controversy, debating their similarities and differences and the boundaries of motor and cognitive dysfunction in these Lewy body disorders. A better understanding of the clinical characterization, neurobiological basis, and progression of cognitive deficits in Lewy body disorders is essential for the development of therapeutic strategies, whether they are geared toward early, mild cognitive deficits or toward the dementia stage.
The Evolution of Cognitive Impairment in PD: From Pre-motor to Late Stage Pre-motor PD
Recent studies characterizing prodromal PD have implicated cognitive changes as part of the pre-motor syndrome (summarized in Table 1 ). Although the studies differ regarding the nature of the cohorts examined (eg, carriers of the glycine to serine substitution at amino acid 2019 [G2019S] mutation in leucine-rich repeat kinase 2 [LRRK2], hyposmic individuals, first-degree relatives of PD patients, healthy individuals) and methodological design (eg, crosssectional vs. longitudinal, different testing paradigms and analyses), they are similar in their findings, which suggest that the principal domain affected in the early stages of nigrostriatal dopamine depletion is executive function, with deficits in working memory, attentional, and verbal fluency tasks reported before motor features of PD become apparent. [15] [16] [17] Further insight into cognitive deficits in the prodromal phase of Lewy body disorders comes from rapid eye movement sleep behavior disorder (RBD) studies. RBD frequently occurs in association with alphasynucleinopathies, including PD and DLB, and can predate these disorders by 5 or more years. 18 About half of "idiopathic" RBD patients will develop an alpha-synucleinopathy after 12 years. 19 Cognitive 
deficits have been documented in RBD; however, in contrast to other pre-motor PD reports, they are not restricted to executive function but also affect memory and visuospatial abilities (reviewed by Gagnon et al. 20 ). This may reflect the fact that RBD is a harbinger of cortical Lewy body pathology rather than PD per se. Furthermore, it highlights the fact that cognitive dysfunction is heterogeneous even at the earliest pathological stages of Lewy body disease.
MCI Prevalence in Established PD
Several studies of incident PD cohorts (n 5 estimate that the prevalence of cognitive deficits or MCI at the time of PD diagnosis is between 19% and 36%. 1, 3, 21, 22 PD-MCI frequencies in prevalent cohorts overlap with these estimates but, due to longer disease durations and methodological differences, may be approximately 50% in some clinic-based cohorts. 23 A multi-center analysis (n 5 1341; mean disease duration, 6.1 years), which defined MCI on the basis of performance 1.5 standard deviations (SD) below normative means in at least one of three domains (attention/executive function, memory, and visuospatial domains), reported a frequency of 25.8% (95% confidence interval, 23.5%-28.2%). 24 Similarly, a recent systematic literature review by a Movement Disorder Society (MDS) Task Force on PD-MCI reported a prevalence of 19% to 38% (mean, 27%). 23 Longitudinal studies suggest that, although cognitive function declines over time, 25 MCI prevalence may remain relatively stable at least in the early years of PD. While new MCI cases emerge, a proportion of patients with existing MCI converts to PDD, and a proportion also reverts to normal cognition. 9, 10 Variation of PD-MCI prevalence estimates across studies reflects, at least in part, differing definitions of impairment. In a study of 119 PD patients, the prevalence of MCI varied from 14% when two neuropsychological tests were impaired in one domain at 2 SD below normative means, to 89% of patients when one abnormal test was required in one domain at 1.0 SD below normal. 26 In another study (n 5 76) using impairment on at least two tests from a comprehensive battery to define PD-MCI, frequency varied from 38% using a 2.5 SD cutoff to 91% using a 1.0 SD cutoff. 27 In an attempt to standardize definitions of MCI in PD, a MDS task force proposed diagnostic criteria, 14 thereby defining a clinical syndrome analogous to MCI in the AD field. The criteria are closely based on the MCI criteria proposed by Petersen and colleagues 28 but encompass aspects specific to PD and provide additional recommendations in terms of neuropsychological testing and subtyping (Table 2) . Debates regarding the merits of a distinct PD-MCI syndrome are discussed below. The MDS PD-MCI criteria still allow for considerable diagnostic variation, depending on the use of abbreviated (level I) or comprehensive (level II) neuropsychological assessments and setting of cutoff values for impairment between 1.0 and 2.0 SD below normative means. Studies to date using the MDS PD-MCI criteria illustrate that prevalence estimates remain highly variable (range, 20%-62%) ( Table 3) ; despite adoption of these standardized criteria, differences in PD cohorts and methodologies likely contribute. The criteria require validation, but one potential difficulty is the lack of a "gold standard" given that PD-MCI is a new construct. The first study to attempt this compared MDS PD-MCI level II criteria with a "consensus diagnosis" of PD-MCI made by three experts. In their clinic-based cohort (n 5 76), they reported an optimal combination of sensitivity (85.4%) and specificity (78.6%) for a 2.0 SD cutoff, compared with cutoffs ranging from 1.0 to 2.5 SD. 27 Estimates of dementia frequency in PD are similarly subject to considerable variation due to methodological differences among studies and a transition over the years from Diagnostic and Statistical Manual (DSM) criteria and/or Mini-Mental State Examination (MMSE) cutoff scores to the MDS-proposed PDD criteria. [31] [32] [33] [34] A large systematic review reported a point prevalence for PDD of 24% to 31%. 35 Because dementia is more prevalent in later stages of PD, a more relevant question may be what proportion of PD patients followed prospectively will ultimately develop dementia. The cumulative incidence of PDD from longitudinal studies of incident PD cohorts is remarkably consistent, suggesting that around half will develop dementia within 10 years from diagnosis (Table 4) .
36-38

Neuropsychological Features of PD Cognitive Dysfunction
Executive function represents the most common cognitive domain affected in PD, early on as well as later in the disease. 3, 21, 27 Deficits can be detected on tests that are sensitive to frontal dysfunction (eg, tests of planning, spatial working memory, and attentional set shifting) 39, 40 and reflect dopaminergic dysfunction in frontostriatal networks. 41 However, impairments in attention, explicit memory, and visuospatial function also are demonstrable in early PD. 3, 21, 42 Some of these cognitive deficits may be secondary, at least in part, to the dysexecutive syndrome (eg, observed improvement in recall with cueing in PD suggests that memory 
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impairment relates to faulty retrieval rather than information storage, 43, 44 and impaired visuospatial performance may relate in part to problems with sequential organization 45 ). Executive dysfunction may occur individually as a single-domain impairment or in combination with other cognitive deficits as multiple-domain impairments. Some, but not all, studies investigating clinical features and frequencies of cognitive impairment in PD patients without dementia reveal that non-memory (nonamnestic) single-domain deficits are the most frequent cognitive subtype. In some of those studies, these non-demented but cognitively impaired PD patients were categorized with "MCI"; however, it should be noted that several studies were conducted prior to the introduction of the term "MCI," and many different neuropsychological tests and definitions for "MCI" in PD have been used. 1, 3, 21, 23, 46, 47 As the field has evolved, subsequent studies have characterized these non-demented but cognitively impaired PD patients as "cognitively normal" or "MCI."
Several studies demonstrate that cognitive deficits in PD are heterogeneous and that cohorts can be stratified by cognitive profile. 1, 21, [47] [48] [49] Deficits in certain cognitive domains (eg, attention/working memory, memory, language, or visuospatial function) may have alternate, non-dopaminergic etiologies (e.g., cholinergic dysfunction, cortical Lewy body, or AD pathology). The MDS PD-MCI criteria provide a framework for domain-specific subtyping by number (single vs. multiple) and by specific cognitive domain affected rather than as "non-memory (nonamnestic) vs. memory (amnestic) MCI subtypes"; this is in contrast to prior MCI criteria (e.g., Petersen et al.) and MCI/AD studies that focused on nonamnestic versus amnestic subtypes. Subtyping of PD-MCI by MDS criteria requires a comprehensive neuropsychological assessment with at least two neuropsychological tests in each of five cognitive domains.
14 Studies employing the MDS PD-MCI criteria to date demonstrate multiple-domain impairment in the majority of patients (> 90% in prevalent cohorts 27, 30 ; 65% in an incident cohort at baseline 10 ). This finding raises questions about whether the current criteria will enable investigations of the progression of individual cognitive-domain PD-MCI subtypes to dementia.
The cognitive profile of PDD remains variable, although it often affects cognitive domains similar to those affected in PD-MCI but with more severe deficits and with the disruption of multiple areas. By definition, PDD includes impairment in at least two cognitive domains but, as per MDS criteria, does not require memory deficits. 33 The predominant cognitive deficits in late PDD are similar to those in DLB, with marked visuospatial dysfunction and fluctuating attention. Impairments in executive function, working memory, and episodic memory are also common in PDD, although language, particularly as measured by object naming, tends to be relatively preserved. 33 
Longitudinal Relationship Between Early Cognitive Impairment and Dementia
Longitudinal studies provide key information on rates of cognitive decline in PD and associated risk factors. Unanswered questions include whether PD-MCI inevitably deteriorates to a state of dementia and whether individual cognitive subtypes have differing prognoses. Historically, many different neuropsychological deficits have been reported as predictors of PDD, including executive function deficits, [50] [51] [52] impaired verbal fluency, 52, 53 visuospatial deficits, 52 memory, and language dysfunction. 51, 54 However, these studies differ in their inclusion of patients at varying disease stages, use of hospital-based cohorts, or non-uniform approaches to neuropsychological testing, and thereby pose challenges for comparing studies and generalizing to broader PD populations.
Several longitudinal studies in population-based, incident PD cohorts with detailed neuropsychological evaluation have been established and will facilitate better descriptions of the pattern and temporal evolution of cognitive dysfunction in PD. Most are still in their early stages, 9,55-57 but the first of these, the CamPaIGN study, 21 recently reported 10-year follow-up data. 58 Analyses at multiple time points in this cohort (n 5 142) indicated that, aside from age, the most significant baseline predictors of later dementia were impaired semantic fluency and pentagon copying (hazard ratios of 3.1 and 2.6, respectively, for dementia at 10 years from diagnosis). 2, 11, 58 There was no association between "frontostriatal-based" executive dysfunction and later dementia; and, in fact, there was no decline in executive function performance over this time. Cognitive functions and certain candidate genes also dissociated in this cohort. A common variant in the microtubule-associated protein tau (MAPT) tau region was strongly associated with earlier dementia, whereas a functional polymorphism in the dopamineregulating enzyme catechol-O-methyltransferase (COMT) was associated with executive dysfunction but not with dementia. Thus, cognitive impairment in early PD may be segregated into 2 types: (1) executive deficits, which are primarily due to dysfunction in dopaminergic frontostriatal networks, are likely to fluctuate with disease course and medications, but are not clearly associated with dementia; and (2) posterior, cortically based deficits, as measured by tests of language (semantic fluency) and visuospatial orientation (pentagon copying), which are due to dysfunction in non-dopaminergic systems, cortical Lewy body deposition, or AD-type pathology and represent the early stages of a dementing process. 58 Other studies support this dissociation. In a study of the PDCognitive Rating Scale, the transition from MCI to dementia was marked by the addition of cortically based deficits to an underlying frontal-subcortically based syndrome. 59 A large meta-analysis of 901 nondemented PD patients who were followed for a mean of 29 months reported significant declines in global cognitive ability, visuospatial function, and memory, but not in executive function. 60 Magnetic resonance imaging studies also suggest that hippocampal and temporoparietal atrophy in early PD predict global cognitive decline, 61 and hypometabolism in posterior cortical regions on positron emission tomography (PET) imaging distinguishes PDD from PD-MCI. 62 Although these regions may also be implicated in AD, the profile of amyloid binding, as measured by Pittsburgh compound B PET imaging, differs in PD patients who have cognitive impairment compared with patients who have AD. 63 These studies also introduced the descriptive terminology of "executive dysfunction" and "posterior-cortical dysfunction" for specific cognitive syndromes in PD. In the current review, we use these terms primarily in the context of the United Kingdom and Spanish PD cohorts described above; however, at present, other PD studies may describe similar cognitive deficits by using the terminology "nonamnestic" or "nonamnestic/amnestic" or may describe a specific individual type of deficit, such as in "executive function, language, or visuospatial" domains.
The relationship between early cognitive deficits and PDD awaits confirmation in studies adopting more standardized definitions of cognitive impairment. 14 Although two longitudinal studies have been published to date using MDS PD-MCI criteria in incident cohorts, neither has explored associations between particular PD-MCI subtypes and dementia, due either to insufficient neuropsychological tests for level II criteria 9 or to small subgroup sizes. 10 Both studies demonstrated that conversion to dementia was more common among patients with PD-MCI than among patients with non-MCI PD greater than 3 years 9 and 5 years 10 after diagnosis. However, 22% reverted from PD-MCI to normal cognition over 3 years 9 ; and, in the other study, 33% of those who developed dementia at 3 years were cognitively normal at baseline. 10 Future studies with larger samples of PD-MCI patients and subtype representation will be needed to dissect out the diagnostic and prognostic values of different types of early cognitive impairment in PD.
Is MCI in PD a Useful Concept?
The concept of MCI as a clinical syndrome in PD has been increasingly recognized over recent years, drawing on the background and lessons of the AD/ MCI field. The term MCI in general was first introduced as a stage in a global cognitive measure, but it has become synonymous with a cognitive syndrome denoting a state of impaired cognitive function not normal for age and suggesting a continuum from normal cognition to dementia, with MCI representing a transitional state. 13, 28, 64, 65 It is recognized, however, that not all MCI patients in general progress to a dementia (ie, some remain stable or revert to normal) 66, 67 and that not all MCI patients progress to AD (ie, nonamnestic subtypes more frequently develop non-AD dementias). 13 In addition, the cognitive deficits in MCI, in contrast to dementia syndromes, do not significantly affect a patient's functional abilities or instrumental activities of daily living. It is also recognized, however, that MCI patients may indeed have some degree of functional impairment. 68, 69 Historically, criteria for MCI developed from longitudinal, epidemiological studies of aging that demonstrated cognitive decline or conversion to dementia in subsets of elderly participants. 13 In recent years, application MCI criteria, or variations therein, emerged in PD populations and thereby generated a more formalized concept of MCI in PD with proposed diagnostic criteria for PD-MCI. The concept of MCI, however, is not without debate or controversy in the AD/MCI field or in the PD arena. The section below examines whether or not PD-MCI is a useful concept using a pointcounterpoint approach.
Point
The introduction of MCI as a concept in PD has led to a beneficial increase in awareness of the cognitive deficits that accompany PD in both the scientific and lay communities. Although the presence of cognitive deficits in non-demented PD has been recognized for many years, the focus of much PD research and therapeutics over the years has been on motor features. PD has now been dubbed the "quintessential neuropsychiatric disease." 70 This represents a long evolution from James Parkinson's observation that the "senses and intellect were uninjured." The concept of PD-MCI has advanced research in the field, with recent years witnessing an explosion of publications on "cognitive impairment in PD" and "MCI in PD" (959 and 341 articles cited in PubMed over the past 5 years, respectively); increased research programs for PD cognition; and a number of clinical trials of symptomatic therapies for PD-MCI. The emergence of PD-MCI has provided an opportunity to develop a framework for understanding the frequency and characteristics of cognitive deficits specifically within the clinical diagnosis of PD, and separate from AD, designated as "PD-MCI." 14 The increased recognition of PD-MCI has positive implications for patients, caregivers, and
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physicians, such as validating previously observed cognitive changes, even early in the disease, as part of PD. This also can lead to appropriate counselling of patients and caregivers, earlier use of compensatory or cognitive strategies, discussions regarding safety and driving, and avoidance of medications with adverse central nervous system effects. Increased awareness of PD-MCI provides an opportunity for more frequent and formalized evaluation of cognition in PD patients, similar to motor assessments that are regularly tracked by clinicians. Cognitive assessments ranging from "bedside" tests to comprehensive neuropsychological evaluations can provide objective measures of cognitive function at baseline and in follow-up. One of the main reasons for the development of PD-MCI as a concept and for standardized diagnostic criteria is the early identification of patients who are at risk of converting to dementia (Fig. 1) . These patients may be best suited for interventions that halt or slow down cognitive decline. An initial step in this identification process involves improving the general characterization of this patient group. Application of the PD-MCI construct provided initial reports of frequencies, clinical phenotypes, and associated biomarkers, first in cross-sectional studies and now with emerging longitudinal follow-up. The use of MCI criteria in PD, whether as modified Petersen's criteria, MDS PD-MCI Task Force criteria, or other definitions, has enabled these patients to be characterized to a degree not previously captured. Studies of incident PD cohorts highlight that PD-MCI patients can be identified early in the course of their cognitive deficits 1, 3, 9, 21 ; thus, future trials may focus on disease-modifying interventions at earlier stages. PD-MCI frequency estimates from incident and prevalent cohorts, along with information from longitudinal studies regarding changes in neuropsychological test scores, clinical status, and other variables, will allow researchers to plan for clinical trials and identify the best predictors for conversion from PD-MCI to PDD. Furthermore, detailed characterization of patients with PD-MCI over recent years has led to the recognition that PD-MCI is more heterogeneous than previously anticipated, with differences in cognitive profiles, underlying neurobiological mechanisms, and rates of progression. 2, 23, 24, [46] [47] [48] 60 Although the MDS PD-MCI criteria do not include biomarkers in the definition of MCI, there is great interest in the identification of biomarkers for PD-MCI and as predictors of conversion to dementia, whether they are cerebrospinal fluid, imaging, genetics, or other. Future studies are needed to establish these biomarkers and whether they ultimately will be incorporated into PD-MCI criteria, as recently done with the revised MCI/ AD criteria. 65 These factors may make the diagnosis of PD-MCI more complex, but they also provide new, important insights into PD-MCI and emphasize that it 
represents a clinical syndrome requiring further research. Over recent years, the need for a uniform definition of PD-MCI for clinical and research purposes became apparent. Whereas early studies added much value in descriptions of PD-MCI, their interpretation was complicated by differences in the definitions and tests used, the populations studied, and other variables. 14, 23, 71 The heterogeneity of PD-MCI across different cohorts could be attributed at least in part to the definitions used. Thus, the MDS Task Force PD-MCI criteria were developed with the goals of providing a standardized definition to be used in identifying (1) the earliest stage of PD cognitive impairment, (2), the best predictors of conversion from PD-MCI to PDD, (3) the effects of PD-MCI on quality of life and daily functioning, (4) patient populations and potential outcome measures for clinical trials, and (5) ways to improve communication among clinicians, patients, caregivers, and researchers.
14 Although validation efforts are underway and several unanswered questions remain, the PD-MCI criteria provide a first step toward a uniform definition that can be used across multiple centers and in clinical research trials.
Counterpoint
In the world of AD, the concept of MCI has caused much debate and confusion. Initially, MCI was seen as a useful way to define prodromal AD and, thus, to facilitate studying patients at the earliest stage of disease, when rescue of neuronal networks might be possible and could make a real difference. 72 With the birth of this concept, a number of articles covering the definition, epidemiology, and treatment of MCI were published. With time, however, many have started to question the concept, because some patients with MCI failed to progress to AD, and other techniques arrived that were deemed better at diagnosing prodromal AD. As such, the original concept of clinically defined MCI has evolved with greater emphasis on early diagnosis using more objective neuropsychological assessments, neuroimaging, and other biomarkers. 73, 74 Although many see the introduction of the MDS PD-MCI diagnostic criteria as a useful step forward in defining more rigorously the exact meaning of MCI in the context of PD, others see it as creating confusion where there was once clarity. 75 For many, the utility of the term PD-MCI is in defining patients who have the earliest cognitive deficits predictive of a dementia rather than displaying cognitive deficits per se. This creates a conundrum to be debated within the field of whether PD-MCI is a static entity or a transitional period.
The heterogeneous nature of cognitive deficits within defined PD-MCI provides another point of confusion. This clinical heterogeneity may reflect a range of different pathologies; thus, lumping all PD-MCI together into a single entity creates confusion both clinically and pathophysiologically and, in the future, likely therapeutically. Some studies demonstrate that there are two distinct types of MCI in PD with divergent etiologies and prognostic implications. 11, 36, 76 As discussed above, studies from the CamPaIGN cohort demonstrate two phenotypes of PD-MCI: an executive dysfunction/frontostriatal type, which is associated with COMT polymorphisms but not with dementia, and a posterior-cortical type with visuospatial and semantic naming deficits, which is associated with MAPT tau haplotypes and heterozygous glucocerebrosidase (GBA) mutations and with the development of early PDD. Lumping these distinct forms of MCI together could interfere with disease-modifying therapy trials for PD-MCI, because not all patients will evolve into a demented state. PD-MCI is not amenable to a reductionist, mechanistic approach, given that these two forms of PD-MCI have different pathophysiologies. Moreover, it does not help the clinician who is advising the patient and caregiver about the prognostic implications of MCI. In addition, whereas the COMT polymorphism and executive dysfunction/frontostriatal type suggest that there are genetic and clinical reasons why some patients with PD-MCI do not progress to dementia, it remains to be seen which factors influence patients with PD-MCI who revert to "normal" on subsequent testing. Many demographic, biological, and clinical variables could be hypothesized to play a role in this.
Not only are there different types of PD-MCI in well-studied cohorts of patients, but there are also other reasons why patients may have PD-MCI independent of these two disease processes. They may be impaired due to a degree of depression or apathy, use of tests that have not been fully validated in the PD population, medications taken, the presence of another disease pathology, or simply being the way they areas is seen in some case series of MCI in the elderly. 77, 78 With these caveats, if the PD-MCI criteria, with their ability to classify subtypes similar to the Petersen criteria (ie, single-domain or multiple-domain impairment, but with specification of the affected domain[s],) can identify a group of high-risk individuals who are likely to develop dementia, then they would be useful, particularly as and when disease-modifying therapies become available. Furthermore, such a position would also facilitate a more detailed evaluation of the underlying pathophysiologies of PD-MCI and, in particular, what drives the dementia of PD. If such a position is not adopted, then there is concern that patients will be sent off to have extensive neuropsychological testing, and many will return with the diagnosis of PD-MCI. Now, the clinician may believe he or she is looking at a different type of PD patient compared
with the cognitively normal PD patient, and the patient may now feel destined to dement. The experimental neurobiologist will want to target diseasemodifying therapy to such a cohort; and, with time, we may end up in the confused world that has haunted the field of AD for decades.
Are PDD and DLB the Same Entity?
DLB is the second most common form of degenerative dementia after AD, with prevalence rates of up to 5% in the elderly and up to 30% of all dementia cases. 79, 80 A related Lewy body disorder is PD, in which dementia may ensue; thus, PD shares many clinical and cognitive features with DLB. 33, 81, 82 At early stages, DLB and PDD are easy to differentiate by the predominance of dementia in DLB and of parkinsonian motor features in PD. 83 Nevertheless, in some patients, dementia and motor signs occur in close succession, provoking debate about their nosology. For research purposes, the "1-year" rule regarding the timing of dementia and parkinsonian features is used. 33, 80 In clinical practice, however, a diagnosis is made based on the relative prominence of the clinical features. The separation between DLB and PDD is considered by some to be artificial, because it implies that the two clinical syndromes have different pathophysiologies. 84 The next point-counterpoint approach explores the conundrum of whether DLB and PDD are the same or different diseases by looking at both their similarities and their differences and by examining the agreements versus controversies yet to be decided.
Clinical Characteristics
Point
There is no single sign or symptom that definitively distinguishes PDD from DLB. In a longitudinal memory/aging study of 100 participants (10 nondemented controls, 40 patients with PD, 15 patients with DLB, and 35 patients with AD), those with DLB and PDD who came to autopsy were nearly identical in all clinical features, including male sex, parkinsonian features, visual hallucinations, sleep disturbances, and neuroleptic sensitivity. 83 One of the unique features of both PDD and DLB, but not of AD, is cognitive fluctuations, with episodes of confusion, hypersomnolence, incoherent speech, and staring spells. These are seen in 15% to 80% of patients with DLB 85 and are also as common in patients with PDD. 86 
Counterpoint
Although there are similarities in the core features of PDD and DLB, the extent of clinical symptoms differs. Resting tremor is not as common in DLB. 79 Parkinsonism usually presents bilaterally in DLB, possibly with more axial rigidity; whereas, in PD, it presents more typically unilaterally and asymmetrically. 79 Sexual disinhibition, alexia, and anomia were more common in DLB than in PDD. 81, 82 In contrast to DLB, motor fluctuations, particularly in later PD stages (when dementia also occurs), add to the substantial burden of advanced PD.
Neuropsychiatric Features
Point Neuropsychiatric features are hallmarks in both PDD and DLB. Depression occurs in 20% to 70% of PD patients, 87 with risk factors including early onset of PD, hallucinations or delusions, and akinetic-rigid presentations. 88, 89 Anxiety co-occurs with depression in up to 40% of PD patients. 90 A history of depression has been reported in 58% of patients with PDD and in 50% of patients with DLB compared with 14% of patients with AD who come to autopsy. 91 Apathy is also common with a 15% frequency in community samples of PD. Similar rates of depression, anxiety, apathy, and phenomenology of mood disorders have been reported in DLB. 92 Visual hallucinations are phenomenologically similar in PDD and DLB. For both conditions, hallucinations tend to be formed and detailed, and they involve anonymous people; although they may also involve family members, animals, body parts, and machines. 33, 80 Counterpoint Although hallucinations may accompany both PDD and DLB, their timing may differ. Visual hallucinations in PD typically occur after chronic dopaminergic therapy, even if their pathogenesis is only partly related to dopaminergic receptor stimulation. In DLB, however, hallucinations may occur spontaneously and earlier, even prior to dopaminergic treatment. 80, 93 Delusions, particularly paranoid or spousal infidelity, are less common than hallucinations in PDD, occurring in 29% of patients in one study, although they were more frequent in PDD patients than in nondemented PD patients. 94 Delusions, however, occur in greater than 50% of DLB patients at first presentation and in approximately two-thirds of DLB patients at some point in their illness. Delusions tend to be more common in DLB than in PDD or AD. Paranoid-type, Capgras syndrome (ie, a delusional misidentification syndrome in which the patient thinks a close family member or friend has been replaced by an identicallooking imposter), and "phantom boarder" delusions are among the most common types in DLB. 95 These may be less common in PDD, although only cases or small series have been reported. 96, 97 Differences in
psychosis in PDD and DLB may be more quantitative than qualitative.
Cognitive Features
Point Both PDD and DLB have prominent executive and visuospatial dysfunction, in contrast to AD. Compared with patients who have AD, patients who have DLB generally show milder deficits on measures of confrontation naming. 98 Individuals with DLB are equally impaired in both the semantic (category) fluency test and the phonemic (letter) fluency test, whereas those with AD perform significantly better on the latter test. 99 Language impairments in PDD also tend to be mild with rare aphasia. Verbal fluency impairments are reliably observed in PDD and occur to a greater degree in PDD than in AD. 100 Semantic fluency deficits in PD, which suggest posterior cortical dysfunction, may be a risk factor for dementia.
2,101
Counterpoint
The frequency of memory deficits, however, may differ between DLB and PDD. Memory deficits are the presenting problem in 67% of patients who have PDD compared with 94% of patients who have DLB and 100% of patients who have AD. 102 Patients with DLB have better recall on verbal memory tests than patients with AD; however, this difference has not been consistently reported, possibly because of the difficulty in isolating pure forms of DLB at autopsy from those with concurrent AD pathology. 103 Remote memory may also be affected by PDD. 104, 105 Relative contributions of Lewy body, AD, or other pathologies may account for some of these differences in cognitive deficits between DLB and PDD.
Other Non-motor Features-Autonomic and Sleep Disturbances
Point
Autonomic features, such as constipation, bladder dysfunction, and orthostatic hypotension, are prominent in many patients with DLB and PDD. Orthostatic hypotension has been observed in many DLB patients and in almost 50% of PDD patients who have longstanding disease. However, true estimates of the prevalence and severity are compounded, particularly in PDD, by other factors like anti-parkinsonian medications, which can exacerbate orthostasis, and in DLB by limited studies. 4 In both DLB and PDD, cardiac scintigraphy with [I-123] metaiodobenzyl guanidine (MIBG) is reduced; although it does not differentiate between alpha-synucleinopathies, MIBG can differentiate Lewy body-related dementias from AD with high sensitivity and specificity. 106 The sleep disturbance RBD frequently occurs in both DLB and PDD and, in both, can precede the onset of cognitive and motor symptoms by many years. 18 
Counterpoint
Whereas autonomic dysfunction is common to both DLB and PDD, the criteria for DLB and PDD differ in their inclusion of this in diagnosis. Among the "supportive" features in DLB criteria are syncope and severe autonomic dysfunction. Although these features are well recognized in PDD, it is interesting that they are not part of the diagnostic criteria for PDD. 33 In the DLB clinical diagnostic criteria, 80 RBD constitutes a "suggestive" diagnostic feature, and its presence may improve the accuracy of diagnostic classification for DLB. 107 
Medication Responses
Point
For cognitive symptoms, it has been suggested that treatment with cholinesterase inhibitors (ChEIs) may be more effective in DLB and PDD than in AD because of their early, prominent central nervous system cholinergic dysfunction. 108 Randomized, doubleblind, placebo-controlled trials support the use of rivastigmine or donepezil in DLB. 109, 110 Rivastigmine is currently approved in the United States and the European Union for treating PDD. 111 For motor deficits, levodopa (L-dopa) and other dopaminergic medications are effective for the treatment of tremor and parkinsonian motor symptoms of PD, including PDD. There are reports of small series of DLB patients whose motor impairments were successfully treated with L-dopa, although the doses used in DLB were generally lower than the doses used in PD. 112 For the treatment of psychosis, atypical antipsychotics (eg quetiapine, clozapine) have been used in DLB and PDD despite limited data on their use in DLB and current evidence-based medicine that favors the use of clozapine in PD. 113 
Counterpoint
Only a few clinical trials of ChEIs in treating cognitive and behavioral aspects of DLB have been conducted, and most guidelines are based on case reports and extensions of AD therapeutic trials. There are no controlled clinical trials of treatments for parkinsonian motor features in DLB. Increased adverse events with the combined use of L-dopa and ChEIs in PD have been reported, although any worsening of tremor or parkinsonism has been mild. 109, 114 However, despite the trials, a Cochrane review does not provide convincing evidence of significant benefits of ChEIs for either DLB or PDD. 115 For motor symptoms, L-dopa and other dopaminergic medications are more effective
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in PD than in DLB, and higher doses can often be used. Psychosis may significantly worsen in DLB after dopaminergic therapies, even at low doses, and this poses a particular challenge. 116 For psychosis treatment, severe neuroleptic sensitivity remains a risk in DLB, although this is encountered less frequently with atypical antipsychotics, which have greater serotonergic profiles. 117 
Pathology and Biomarkers
Point
Studies demonstrate that Lewy bodies composed of alpha-synuclein are the predominant cause of dementia in both PD and DLB. 118, 119 Whether the ascending progression of Lewy body pathology described by Braak and colleagues in non-demented PD also applies to DLB is unclear, with some studies suggesting the possibility of a descending pattern of progression in some patients. [120] [121] [122] In nearly all studies of DLB and PDD, variable amounts of AD pathology, mostly in the form of amyloid, contribute to the pathologic burden. This shared neuropathology may explain the similar appearances of DLB and PDD in structural and metabolic imaging studies; although, in some studies, a greater amyloid burden has been detected on imaging in DLB. [123] [124] [125] There may also be variable amounts of cerebrovascular disease in both DLB and PDD, but the extent to which this pathology contributes to clinical symptoms is unclear. Cerebrospinal fluid analyses for alpha-synuclein, amyloid, and tau do not clearly distinguish DLB and PDD, although results have been variable. [126] [127] [128] These biomarker studies, however, potentially may help distinguish DLB and/or PDD from AD.
Counterpoint
It should be noted, however, that approximately 80% of DLB cases have sufficient AD pathology to be considered a mixed dementia. 100 This is not so in PDD, in which three neuropathological profiles may be present: one-third with only neocortical Lewy bodies, one-third with AD pathology, and one-third with only subcortical pathology. 82 In a study examining Lewy body and AD pathology as a function of dementia severity in PDD, the severity of cortical Lewy body pathology was positively associated with dementia, whereas 29% of all patients with PD had sufficient pathology for comorbid AD. 129 Combined Lewy body and AD pathology was correlated with a later age at PD onset, a higher Lewy body burden, and a greater degree of cerebral amyloid angiopathy. 129 Furthermore, in a subgroup of patients with severe PDD, the cortical tau burden was markedly increased, suggesting that progressive dementia is a product of extensive cortical neurofibrillary tangles. 119 
The Debate Remains
If one were to draw a conclusion from these arguments, then PDD and DLB should be considered disorders that share many common features and pathologies. Yet not all features are identical. Early amyloid deposits in DLB relative to PDD may account for differences in the timing of dementia and motor findings. Later appearance of tau pathology may hasten the severity of symptoms as dementia progresses. For these reasons, studying prodromal states of DLB and PDD, including pre-dementia (ie, MCI) or premotor stages, may yield the best answers regarding whether they are the same or different disorders.
Conclusion
The spectrum of cognitive impairment in Lewy body disease is indeed broad, with symptoms potentially present even at pre-motor stages through advanced disease. The cognitive phenotypes of PD, PDD, and DLB are heterogeneous, thereby prompting debate regarding optimal categorizations for diagnosis and prognosis. Early cognitive deficits may further blur diagnostic boundaries between PDD and DLB, particularly when considering MCI as a transitional state, preceding dementia. Findings from recent studies and ongoing debates on PD-MCI and PDD/DLB illustrate the growth of the field of cognition in Lewy body disorders, a move away from traditional or dopaminergic models of disease, and the opportunity for wellneeded, safe, and effective therapies.
